ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

ADMS Adamas Pharmaceuticals Inc

8.22
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Adamas Pharmaceuticals Inc NASDAQ:ADMS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 8.22 9.33 8.30 0 01:00:00

Adamas to Present at Upcoming September Investor Conferences

30/08/2021 9:11pm

Business Wire


Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart


From Jul 2021 to Jul 2024

Click Here for more Adamas Pharmaceuticals Charts.

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that management will present at the following virtual investor conferences during the month of September 2021:

  • H.C. Wainwright 23rd Annual Global Investment Conference, a pre-recorded presentation will be available beginning on Monday, September 13 at 7:00 am ET (4:00 am PT)
  • Cantor Fitzgerald Global Healthcare Conference, on Wednesday, September 29 at 4:40 pm ET (1:40 pm PT)

Replays of both events will be available on the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations. The replays will remain available for approximately 30 days from their original posting.

About Adamas Pharmaceuticals, Inc.

At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and, society. We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.

Media: Sarah Mathieson Vice President, Corporate Communications 510-450-3528 smathieson@adamaspharma.com Investors: Peter Vozzo Managing Director Westwicke/ICR 443-213-0505 peter.vozzo@westwicke.com

1 Year Adamas Pharmaceuticals Chart

1 Year Adamas Pharmaceuticals Chart

1 Month Adamas Pharmaceuticals Chart

1 Month Adamas Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock